Lakefront Biotherapeutics (LKFT) Return on Invested Capital (2017 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Return on Invested Capital for 10 consecutive years, with 0.1% the latest figure, recorded in Q1 2026.

• Quarterly Return on Invested Capital rose 12.0% year-over-year to 0.1% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.1% (up 12.0% YoY) and the FY2025 annual result came in at 0.05%, up 5.0% from the prior year.
• Return on Invested Capital grew to 0.1% in Q1 2026 per LKFT's latest filing, from 0.05% in the prior quarter.
• Over the last five years, Return on Invested Capital for LKFT reached as high as 0.1% in Q1 2026 and fell as low as 0.04% in Q3 2025.
• A 5-year average of 0.0% and a median of 0.01% in 2024 frame the typical range for Return on Invested Capital.
• Annual changes were most pronounced in 2025 — Return on Invested Capital dropped 5 bps — and 2026, when it increased 12 bps.
• Year by year, Return on Invested Capital stood at 0.01% in 2022, then jumped by 207 bps to 0.01% in 2023, then slumped by 163 bps to 0.01% in 2024, then soared by 699 bps to 0.05% in 2025, then jumped by 124 bps to 0.1% in 2026.
• According to Business Quant data, Return on Invested Capital over the past three periods registered 0.1%, 0.05%, and 0.04% for Q1 2026, Q4 2025, and Q3 2025 respectively.